Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Sköld, C MBendstrup, E
Myllärniemi, M
Gudmundsson, G
Sjåheim, T
Hilberg, O
Altraja, A
Kaarteenaho, R
Ferrara, G
Issue Date
2017-02
Metadata
Show full item recordCitation
Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. 2017, 281 (2):149-166 J. Intern. Med.Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal progressive lung disease occurring in adults. In the last decade, the results of a number of clinical trials based on the updated disease classification have been published. The registration of pirfenidone and nintedanib, the first two pharmacological treatment options approved for IPF, marks a new chapter in the management of patients with this disease. Other nonpharmacological treatments such as lung transplantation, rehabilitation and palliation have also been shown to be beneficial for these patients. In this review, past and present management is discussed based on a comprehensive literature search. A treatment algorithm is presented based on available evidence and our overall clinical experience. In addition, unmet needs with regard to treatment are highlighted and discussed. We describe the development of various treatment options for IPF from the first consensus to recent guidelines based on evidence from large-scale, multinational, randomized clinical trials, which have led to registration of the first drugs for IPF.Description
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/Open To access publisher's full text version of this article click on the hyperlink at the bottom of the pageAdditional Links
http://onlinelibrary.wiley.com/doi/10.1111/joim.12571/pdfRights
Archived with thanks to Journal of internal medicineae974a485f413a2113503eed53cd6c53
10.1111/joim.12571
Scopus Count
Collections
Related articles
- Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
- Authors: Sathiyamoorthy G, Sehgal S, Ashton RW
- Issue date: 2017 Jun
- Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
- Authors: Hayton C, Chaudhuri N
- Issue date: 2017 Sep
- Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
- Authors: Jo HE, Troy LK, Keir G, Chambers DC, Holland A, Goh N, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford H, Chapman S, Reynolds PN, Glaspole I, Beatson D, Jones L, Hopkins P, Corte TJ
- Issue date: 2017 Oct
- Therapeutic targets in idiopathic pulmonary fibrosis.
- Authors: Kolb M, Bonella F, Wollin L
- Issue date: 2017 Oct
- Therapeutic advances in idiopathic pulmonary fibrosis.
- Authors: Fraser E, Hoyles RK
- Issue date: 2016 Feb